A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer

Primary Objective

To evaluate the use of Enfortumab vedotin plus CPI in treatment of advanced bladder cancer

This Study is
No Longer Enrolling

Details
Age

Adult

Type of Study

Treatment

Locations

University of Colorado Hospital

Study ID

Protocol Number: 17-1410

More information available at ClinicalTrials.gov: NCT03288545

Categories

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers